INFLUENCE OF RESISTIN ON THE COURSE OF ISCHEMIC HEART DISEASE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Relevance. Through dermal coronary intravascular revascularization by means of stenting is an effective method of treatment CHD patients with the type 2 diabets. At the same time frequency of stents restenosing for this special cohort of patients is fluctuating from 12 by 40 %.

Objective. To study prognostic significance of the new biomarker of intravascular inflammation of resisin in blood of CHD patients with DM 2 who suffered from stenting. Material and methods. In the study 60 patients (48 men and 12 women, in the middle age 60.9 years) with CHD and DM2 are included. The patients were divided into two groups: Patients with positive progress of comorbide pathology belonged to the first group (n = 30); in the second group (n =3 0) patients with unfavorable progress of cardiac vessel pathology were included. The further observation was carried during 12 months. Content of all the patients in blood of resistin with help of enzyme immunoassay analysis was determined, as well as lipid blood serum mixture and additional metabolic risk factors. By the indications control a coronary angiography was conducted. Restenosis of coronary arteries was counted as the narrowing of a coronal artery lumen of ≥70% in the place of an intervention.

The result. Unfavorable flow, including restenosis of coronary arteries was revealed in 30 cases (50%). ROC-analysis showed great predictive significance of resistin – (area under a curve >5/35, Sensitivity 86.2, Specificit 70.0) in development of constrictive coronary atherosclerosis restenosis of coronary arteries after their stenosis.

The conclusion. The study of resistin level in DM patients blood for the valuation of the disease prognosis and optimization of the tactics for choice of coronary pathology treatment seems expedient and informative. 

1. Dedov I.I., Shestakova M.V. Saharnyi diabet. Rukovodstvo dlya vrachey [Diabetes Mellitus. Guideline]. Moscow, 2003. (in Russian).

2. Danilov N.M., Gorgadze T.G., Chazova I.Ye. Faktory riska restenoza posle koronarnogo stentirovaniya u bolnih s metabolicheskim sindromom [Risk restenosis factors for coronary bypass patients with metabolic syndrome]. Kardiovaskulyarnaya terapiya i profilaktika - Cardiovascular Therapy and Prevention, 2007, no. 6, pp. 71-74 (in Russian).

3. Chumakova G.A., Veselovskaya N.G., Ott A.V., Gritsenko O.V. Metabolicheskiy sindrom: Slozhnye i nereshennye problemy [Metabolic syndrome: challenging and unresolved issues]. Rossiyskiy kardiologicheskiy zhurnal - Russian Journal of Cardiology, 2014, no. 3, pp. 63-71 (in Russian).

4. On Y.K., Park H.K., Hyon M.S., Jeon E.S. Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients. Cirs. J., 2007, no. 71, pp. 868- 873.

5. Momiyama Y., Ohmori R., Uto-Kondo H., Tanaka N., Kato R., Taniguchi H., Arakawa K., Nakamura H., Ohsuzu F. Serum resistin levels and cardiovascular events in patients undergoing percutaneous coronary intervention. J. Atheroscler. Thromb., 2011, no. 18, pp. 108-114.

6. Lowe H.C., Oesterle S.N., Khachigian L.M. Coronary in stent restenosis: current status and future strategies. Am. Coll. Cardiol., 2002, no. 39 (2), pp. 183-193.

7. Piatti P.M., Colombo A., Carlo D.M. et al. Association of Insulin resistance, hyperleptinemia and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting. Circulation, 2003, no. 108, pp. 2074-2081.

8. Teplyakov A.T. Khronicheskaya serdechnaya nedostatochnost’. Tsitokinovaya ekspressiya, immunnaya aktivatsiya i shchita organov-misheney [Chronie heart failure. Cytokinin expression, immune activation and protection of target organs]. Tomsk, Tomsk State University Publ., 2012, 294 p. (in Russian).

9. Havel P.I. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein and adionectin. Curr. Open Lipidol., 2002, no. 13, pp. 51- 59.

10. Silha I.V., Krsek M, Skrha I. V., Sucharda P., Nyomba B. L. Plasma resistin, adiponectin and leptin levels in lean and obese subjects. Correlation with insulin resistance. Eur. I Endocrinol., 2003, no. 149, pp. 331-335.

11. McTernan P.G., Fisher F.M., Valsamaris G. et al. Resistin and type 2 diabetes: Regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human olifferentiated adipocytes. I Clin. Endocrinol. Metab., 2003, no. 88, pp. 6098-6106.

12. Kim M., Oh I.K., Sacata S. et al. Role of resistin in cardiac contractility and hypertention. I Moll. Cell. Cardiol., 2008, no. 45 (2), pp. 270-280.

13. Menzaghi C., Bacci S., Salvemini L. et al. Serum resistin cardiovascular disease and all-cause mortality in patients with type 2 diabetes. PLOS ONE, 2013, no. 8(6), e 64729. https://doi.org/10, 1371/ journal.pone.0064729.

14. Aleksandrov A.A., Shatskaya O.A., Kukharenko S.S., Yadrikhinskaya M.N., Abdalkina Ye. N., Drozdova Ye.N., Shestakov M.V. Rezistin i diabeticheskaya kardiomiopatiya: patogeneticheskiye vzaimosvyazi [Resistin and diabetic cardiomyopathy: pathogenetic relationship]. Consilium Medicum [kardiologiya], 2014, vol. 16, no. 10, pp. 109-116 (in Russian).

15. Diagnostika SD 2 tipa. Rekomendatsii ekspertov VOZ [Type 2 diabetes mellitus. Guideline of WHO]. Rossiyskiy kardiologicheskiy zhurnal - Russian Journal of Cardiology, 2014, no. 3 (107), pp. 7-61 (in Russian).

16. Ohmori R., Momiyama Y., Kato R., Tariguchi H., Ogura M., Ayaori M., Nakamura H., Ohsuzu F. Associations between serum resistin levels and insulin resistance, in flammarion and coronary artery disease. I Am. Coll. Cardial., 2005, no. 46, pp. 379-382.

17. Holcomb I.N., Kobakoff R.C., Chan B. et al. FIZZI, a novel cysteine - rich secreted protein associated with pulmonary inflammation, defines a new gone family. EMBO I, 2000, no. 19, pp. 4046-4055.

18. Borst S.E. The role of TNF-α in insulin resistence. Endocrine, 2004, no. 23, pp. 177-182.

19. Osawa H., Yamada K., Onuma H. et al. The G/G genotype of a resistin single-nucleotide 3 polymorphism at-420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp 1/3. Am. I. Hum. Gren., 2004, no. 75, pp. 678-686.

20. Takeishi Y., Niizeri T., Arimoto T. et al. Serum resistin is associated with high risk in patients with congestive heart failure: a novel link is metabolic signals and heart failure. Circ. I., 2007, no. 71, pp. 460-464.

21. Ding Q., Chai H., Mahmood N. et al. Matrix metalloproteinase modulated by protein kinase Ce mediate resistin - induced migration of human coronary artery smooth muscle cells. I. Vasc. Surg., 2011, no. 53 (4), pp. 1044-1051.

22. Colabro P., Samudio I., Willerson I.T., Yeh ETH. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal regulated kinase ½ and phosphatidylinositol 3-kinese pathways. Circulation, 2004, no. 110, pp. 3335-3340.

23. Chen C., Jiang J., Lu J. M. et al. Resistin decreases expression of endothelial oxide synthase through oxidative stress in human coronary artery endothelial cells. Am. J. Physiol., 2010, no. 299, pp. H 193-H 201.

24. Park H.K., Ahima R.S. Resistin in rodents and humans. Diabetes Metab., 2013, no. 37, pp. 404-414.

25. Osawa H., Tabora Y., Kawamoto R. et al. Plasma resistin, associated with single nucleotide polymorphism - 420, is correlation insulin resistance, lower HDL cholesterol and high-sensitivity C-reactive protein in the Japanese population. Diabetes Care, 2007, no. 30, pp. 1501-1506.